Skip to main content Accessibility help
×
Hostname: page-component-77c78cf97d-7rbh8 Total loading time: 0 Render date: 2026-04-27T07:16:51.786Z Has data issue: false hasContentIssue false

Chapter 18 - Precursor Lymphoid Neoplasms

from Section IV - Neoplastic Disorders of Bone Marrow

Published online by Cambridge University Press:  25 January 2024

By
Virginia Knez ,
Alexandra E. Kovach ,
Gordana Raca ,
Billie Carstens  and
Xiayuan Liang
Edited by
Xiayuan Liang ,
Bradford Siegele  and
Jennifer Picarsic
Xiayuan Liang
Affiliation:
Children’s Hospital of Colorado
Bradford Siegele
Affiliation:
Children’s Hospital of Colorado
Jennifer Picarsic
Affiliation:
Cincinnati Childrens Hospital Medicine Center
Get access

Summary

Lymphoblastic leukemias/lymphomas constitute a family of malignant lymphoid neoplasms that morphologically and immunophenotypically recapitulate the features of early lymphoid precursors of either B- or T-cell origin [1–4]. The distinction between acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) is arbitrary [4]. The term LBL is used when the disease is confined to a predominant extramedullary mass lesion with no or minimal involvement (<25%) of peripheral blood and bone marrow (BM). The cases with ≥25% blasts in either peripheral blood or BM are staged and treated as ALL [1,4].

ALL and LBL have many characteristics in common. They are morphologically indistinguishable, share similar immunophenotypes, and have overlapping cytogenetic profiles. It is generally believed that the two entities are biologically equivalent, represent a clinical continuum or different stages of the same disease, and are categorized as such by the 2017 World Health Organization (WHO) classification scheme [2–5].

Information

Type
Chapter
Information
Pediatric Pathology of Hematopoietic and Histiocytic Disorders , pp. 208 - 226
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Onciu, M. Precursor lymphoid neoplasms. In: Proytcheva, MA, ed. Diagnostic pediatric hematopathology. Cambridge, UK: Cambridge University Press; 2011:323–44.Google Scholar
Borowitz, MJ, Chan, JKC, Downing, JR, et al. B-lymphoblastic leukaemia/lymphoma, not otherwise specified. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:200–2.Google Scholar
Borowitz, MJ, Chan, JKC, Bene, MC, et al. T-lymphoblastic leukaemia/lymphoma. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:209–13.Google Scholar
Duffield, AS, Racke, FK, Borowitz, MJ. Precursor B- and T-cell neoplasms. In: Jaffe, ES, Arber, DA, Campo, E, et al., eds. Hematopathology, 2nd ed. Philadelphia, PA: Elsevier;2017:761–73.Google Scholar
Borowitz, MJ, Chan, JKC, Downing, JR, et al. B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed.Lyon, France: IARC Press; 2017:203–9.Google Scholar
Bennett, JM, Catovaky, D, Daniel, MT et al. Proposals for the classification of the acute leukaemia. Br. J. Haematol. 1976; 33:451–8.Google Scholar
Malard, F, Mohty, M. Acute lymphoblastic leukaemia. Lancet. 2020. 395:1146–62.Google Scholar
Inaba, H, Mullighan, CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524–39.Google Scholar
Holmfeldt, L, Wei, L, Diaz-Flores, E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242–52.Google Scholar
Moriyama, T, Metzger, ML, Wu, G, et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol. 2015;16:1659–66.Google Scholar
Shah, S, Schrader, KA, Waanders, E, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45:1226–31.CrossRefGoogle ScholarPubMed
Noetzli, L, Lo, RW, Lee-Sherick, AB, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47:535–8.Google Scholar
Knez, V, Liu, X, Schowinsky, J, et al. Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: A multi-institutional study. Leuk Lymphoma. 2019;60:1006–13.Google Scholar
Valbuena, JR, Medeiros, LJ, Rassidakis, GZ, et al. Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2006;126:235–40.Google Scholar
Hashimoto, M, Yamashita, Y, Mori, N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol. 2002;197:341–7.Google Scholar
Gohring, G, Michalva, K, Beverloo, B, et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood. 2010;116:3766–9.Google Scholar
Knez, V, Bao, L, Carstens, B, et al. Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood. Leuk Lymphoma. 2020;61:2129–35.Google Scholar
Ramakers-van Woerden, NL, Pieters, R, Loonen, AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96:1094–9.Google Scholar
Nachman, JB, Heerema, NA, Sather, H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007;110:1112–5.CrossRefGoogle ScholarPubMed
Den Boer, ML, van Slegtenhorst, M, De Menezes, RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125–34.CrossRefGoogle ScholarPubMed
Yadav, V, Ganesan, P, Veeramani, R, et al. Philadelphia-like acute lymphoblastic leukemia: a systematic review. Clin Lymphoma Myeloma Leuk. 2021;21:e57–e65.Google Scholar
Wenzinger, C, Williams, E, Gru, AA. Updates in the pathology of precursor lymphoid neoplasms in the revised fourth edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Curr Hematol Malig Rep. 2018;13:275–88.Google Scholar
Khan, M, Siddiqi, R, Tran, TH. Philadelphia chromosome-like acute lymphoblastic leukemia: a review of the genetic basis, clinical features, and therapeutic options. Semi Hematol. 2018;55:235–41.Google Scholar
Loh, ML, Zhang, J, Harvey, RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children’s Oncology Group TARGET Project. Blood. 2013;121:485–8.CrossRefGoogle ScholarPubMed
Lyapichev, KA, Sukswai, N, Angelova, E, et al. CD123 expression in Philadelphia chromosome-like B acute lymphoblastic leukemia/lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21:e317–e20.Google Scholar
Sadras, T, Heatley, SL, Kok, CH, et al. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Lett. 2017;408:92–101.Google Scholar
Yap, KL, Furtado, LV, Kiyotani, K, et al. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017;58:950–8.Google Scholar
Harrison, CJ. Blood spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. Blood. 2015;125:1383–6.Google Scholar
Lilljebjorn, H, Henningsson, R, Hyrenius-Wittsten, A, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7:11790.Google Scholar
Zhang, J, McCastlain, K, Yoshihara, H, et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016;48:1481–9.CrossRefGoogle Scholar
Dib, C, Zakharova, V, Popova, E, et al. DUX4 pathological expression: causes and consequences in cancer. Trends Cancer. 2019;5:268–71.Google Scholar
Tian, L, Shao, Y, Nance, S, et al. Long-read sequencing unveils IGH-DUX4 translocation into the silenced IGH allele in B-cell acute lymphoblastic leukemia. Nat Commun. 2019;10:2789.Google Scholar
Tanaka, Y, Kawazu, M, Yasuda, T, et al. Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia. Haematologica. 2018;103:e522–e6.Google Scholar
Rehn, JA, O’Connor, MJ, White, DL, et al. DUX hunting – clinical features and diagnostic challenges associated with DUX4-Rearranged leukaemia. Cancers (Basel). 2020;12.Google Scholar
Schinnerl, D, Mejstrikova, E, Schumich, A, et al. CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia. Haematologica. 2019;104:e352–e5.Google Scholar
Novakova, M, Zaliova, M, Fiser, K, et al. DUX4 r, ZNF384 r and PAX5-P80 R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch. Haematologica. 2021;106:2066–75.Google Scholar
Ueno, H, Yoshida, K, Shiozawa, Y, et al. The prognostic value of TP53 mutations depends on clinical backgrounds in pediatric patients with acute lymphoblastic leukemia. Blood. 2018;132 (Suppl 1):4077.Google Scholar
Borowitz, MJ, Chan, JKC, Bene, MC, et al. T-lymphoblastic leukaemia/lymphoma. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:209–13.Google Scholar
Kurtin, P. Thymus gland. In: Collins, RD, Swerdlow, SH, eds. Pediatric hematopathology. Philadelphia, PA: Churchill Livingstone; 2001:323–41.Google Scholar
Borowitz, MJ, Bene, MC, Harris, NL, et al. NK-lymphoblastic leukaemia/lymphoma. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:213.Google Scholar

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the HTML of this chapter is currently unknown and may be updated in the future.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×